Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIAION
2024-519977-20-00Phase 2Completed
- Sponsor
- Quinze-Vingts Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in anterior ischemic optic neuropathy (AION) and giant cell arteritis (GCA) (2 arms), sponsored by Quinze-Vingts Hospital. Primary endpoint: Ocular improvement at week 8. Started Jan 2025; status: completed.
02
Drugs
tocilizumab
03
Conditions
anterior ischemic optic neuropathy (AION)giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-519977-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519977-20-00.